GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » Short Percentage of Float

Ascelia Pharma AB (FRA:7ZA) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Ascelia Pharma AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Ascelia Pharma AB's Short Percentage of Float

For the Biotechnology subindustry, Ascelia Pharma AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascelia Pharma AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's Short Percentage of Float falls into.


;
;

Ascelia Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:ISOFOL OSTO:XBRANE OSTO:LIPUM XSAT:CESSA OSTO:IVACC OSTO:XINT OSTO:GUARD OSTO:IMMU OSTO:KDEV OSTO:IRLAB A VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ACE:Sweden
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Website
https://www.ascelia.com
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines